Ki 16425 (Ki16425)是竞争性的溶血磷脂酸受体(LPA)亚型可逆的选择性拮抗剂，作用于LPA1/2/3的K_i值为0.34 μM，6.5 μM和0.93 μM，对LPA4/5/6无明显活性。Ki16425按照LPA1 ≥LPA3 >> LPA2的递减顺序抑制LPA诱导的反应，抑制LPA诱导的鸟苷5'-O-(3-硫代三磷酸)结合和膜成分结合，还抑制LPA 诱导的长期反应，包括DNA合成和细胞迁移。

参考文献

[1] Ohta H, et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.Mol Pharmacol. 2003 Oct;64(4):994-1005.

[2] Yu FX, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012 Aug 17;150(4):780-91.

[3] Ma L, et al. Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist. J Neurochem. 2009 Apr;109(2):603-10.

冰袋运输。粉末直接保存于-25~-15℃，有效期3年。建议分装后-25~-15℃干燥保存，避免反复冻融。